Chemeleon
Rapid, instrument-free diagnostic platform providing at-home and POC colorimetric assays.
Founded
2013Rapid, instrument-free diagnostic platform providing at-home and POC colorimetric assays.
Chemeleon was founded with the mission to revolutionize point-of-care diagnostics through its innovative platform technology. The company's vision is to make rapid, accurate, and affordable diagnostic testing accessible to everyone, anywhere. Chemeleon's core product is an instrument-free, in vitro diagnostic assay that delivers colorimetric readouts in minutes, enabling at-home and point-of-care (POC) testing without the need for specialized equipment or training. Their technology can detect a wide range of analytes, including drugs, proteins, and viruses, making it versatile for various medical and health-related applications.
Notable figures affiliated with Chemeleon include experts in biotechnology and healthcare innovation, though specific names are not provided. The company has attracted significant interest from investors focused on disruptive healthcare technologies. Key achievements include the successful development and deployment of their proprietary sample-to-answer diagnostic platform, which has demonstrated the potential to transform decentralized testing. Chemeleon's impact lies in its ability to provide rapid and reliable diagnostics, potentially improving healthcare outcomes by enabling timely and accurate disease detection and management.
Companies similar to Chemeleon include Instadiagnostics, Prompt Diagnostics, Test Diagnostics and Luminostics.
Chemeleon was founded in 2013.
Chemeleon's headquarters is located in New York, US.
Chemeleon's most recent funding round was for $1.7M (USD) in January 2023.
As of Jan 2, 2023, Chemeleon has raised a total of $6.1M (USD).
Chemeleon has 6 employees as of Feb 4, 2024.
Test Diagnostics
